HFS
VYGR icon

Hughes Financial Services’s Voyager Therapeutics VYGR Stock Holding History

Hughes Financial Services’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-157
Closed -$534 – 1114
2025
Q2 		$534 Buy
+157
New +$506 ﹤0.01% 928

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Hughes Financial Services's VYGR Position: Q3 2025 in Review

Hughes Financial Services sold out of Voyager Therapeutics (VYGR) in Q3 2025, closing a stake of 157 shares — an estimated $534 sold.

Hughes Financial Services first reported a position in VYGR in Q2 2025 and held it in 1 quarter. The position peaked at $534 in Q2 2025. 117 funds tracked by Wall St. Rank hold VYGR as of Q3 2025.

  • Hughes Financial Services reported no remaining Voyager Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Hughes Financial Services sold 157 Voyager Therapeutics shares in Q3 2025, an estimated $534.
  • Hughes Financial Services first reported a position in Voyager Therapeutics in Q2 2025 and held it in 1 quarter.
  • Hughes Financial Services's Voyager Therapeutics position peaked at $534 in Q2 2025.
  • 117 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2025.

Based on Hughes Financial Services's 13F filing for Q3 2025, filed 14 Nov 2025.